AGENDA DAY 1

 

Microbiome World Congress USA Day 1 2017

8:50 Chairperson’s Opening Remarks

TURNING RESEARCH INTO VIABLE THERAPEUTICS

09:00

Keynote Address: The new paradigm of treatment: Understanding the relationship between ecology and medicine in unlocking the potential of the microbiome

  • What is the current state of the field and how have new techniques in molecular biology enabled us to probe the microbiome and better understand its diversity and biological significance?
  • When dealing with living organisms- How does microbial ecology differ from classical drug therapies, and classical medical statistics?
  • What areas have we seen greatest progress and how do we avoid overselling microbiome potential and current state before we have solid evidence of translational capacity?
Scientific
09:40

Presentation: Re-assessing ethical issues in Microbiome research and medicine

  • What implications does Microbiome Research have on our social and legal systems?
  • Studies to advance personalized medicine will require broad public participation to provide sufficient material for biobanks and sample banks rather than a small sample of people with a target condition. 
  • How does this change the focus from the individual to community solidarity?
10:00

10:00 Speed Networking

10:20 Networking coffee break

CLINICAL TRIAL DESIGN, DATA AND PATIENT RECRUITMENT

11:00

FDA update: points to consider in when developing Microbiome treatments

  • Challenges in developing microbial treatments
  • Regulatory implications of C. Difficile- microbiome- Host interactions.
  • Understanding current guidelines for living biological samples.
Philip John Brooks
11:20

Presentation: Clinical innovations in Microbiome: From wellness to treatment

  • The proper regulation of Microbiome is essential if the field is to be taken seriously as a viable treatment for diseases.
  • How do we move away from the wild west like scene of dietary supplements?
  • What can we learn from recent partnerships and breakthroughs?
Scientific
11:40

Presentation: The great potential and limitations of the mouse model

  • With mouse models being standard models why do we often see such varying results?
  • What microbiome communities are essential to lab mice?
  • Can cohabiting mice with common mice offer stronger research subjects that better replicate the human immune system?

12:00 ROUNDTABLES

Roundtable 1: Mouse Models: The great potential and limitations of the mouse model

Roundtable 2: Skin microbiome: How do you develop various carbohydrate-polymer conjugates as selective fermentation inducers (SFIs) for editing skin microbiome?

Roundtable 5: Microbiome of the built environment: from research to application

Roundtable 6: Sponsorship Available

If you are interested in sponsoring the moderation of a roundtable contact Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

12:40 LUNCH

DRUG DEVELOPMENT- BIOMARKER

Commercial
14:00

Panel: Cutting through the confusion of bioinformatics

  • Why do our models seem to break down when ecology meets the worlds of statistics and medicine?
  • How do we continue to identify the stable sub communities?
  • What bacterial interactions can we look to outside of our immediate field?
Scientific
14:40

Presentation: The Microbiome and Multiple Sclerosis

  • How can the Gut Microbiome shape host immunity and communicate with CNS via Gut Brain Axis?
  • What microbes, genes and metabolites have been identified that protect from autoimmunity?
  • How does the gut microbiome affect treatment efficiency of MS drugs in Mouse models?
Commercial
14:40

Presentation: Developments of Targeted Therapy via Microbiome Community

  • The level of uniqueness in the microbiome make up means far more
  • How can we enhance sampling protocols with high quality metagenomic data?
  • How in depth must we go to identify key bacteria of interest?
  • With current treatments having wide ranging responses in patients- How personalized does each treatment need to be?
Scientific
14:50

Sponsored case study

DRUG DEVELOPMENT- DIAGNOSTIC VALIDATION

Commercial
15:00

Personalized nutrition for the microbiome

  • With microbiome and nutrition becoming more synergistic how close are we to moving prediction and prevention with dietary changes?
  • Looking at current data- How can we interpret the current state of individualized microbiome responses to various foods and healthy and diseased states?
  • What does this mean for the future of food and for the treatment landscape?
Commercial
15:20

Presentation: The elite Athlete microbiome - what makes top athletes so unique?

  • How can we utilize next-generation sequencing to understand what makes elite athletes unique?
  • What changes are we seeing pre and post sport activity?
  • What does this mean in the next generation of athletes?
  • Are we seeing key markers for endurance, fatigue and recovery?
  • How can this be used to aid the wider population?
Commercial
15:40

Presentation: Harnessing nature to help farmers sustainably feed the planet

  • How do we increase agricultural activity while not relying on technology of the high yields gains of the past?
  • What is being done to isolate the endophytes of various plants and how can this improve drought resistance, nutrient absorption, etc?
  • What real-life examples have we seen of the benefits of these enhanced food and crops?
Scientific
15:50

Presentation: How precisely targeted drugs are changing the behaviour of the microbiome

  • With the billions of possible microbes the task of identifying and verifying a positive lead is key to effective drug development.
  • With bacterial communities being so specific to regions how do we optimize best combinations?
  • How can we take advantage of Synthetic Biotics to enhance and encourage healthy interactions?
Commercial
15:50

Sponsored case study

16:00 Networking coffee break

Closing keynotes

16:40

Keynote: A chemical understanding of the Gut Microbiome

  • Uncovering how and why bacteria metabolize bile acids?
  • How do these bile acids influence biological processes?
  • How can we make use of this to better monitor and alter bacterial metabolism in vivo?
17:00

Keynote:  A large pharma perspective on the microbiome

  • How does Pfizer evaluate opportunities in the microbiome?
  • What developments in the field is Pfizer monitoring most closely?
  • What capabilities does Pfizer consider most valuable in biotech partners?

17:20 Closing Remarks

17:30 Drinks Reception

last published: 11/Oct/17 14:25 GMT